Vicarious Surgical (RBOT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Special Meeting scheduled for July 21, 2026, to vote on an assignment for the benefit of creditors followed by voluntary dissolution and liquidation under a Plan of Dissolution.
Board unanimously recommends approval, citing ongoing losses, inability to secure financing, and lack of viable alternatives.
If approved, all assets will be assigned to a third-party assignee for liquidation, with proceeds used to pay creditors; distributions to stockholders are unlikely.
Upon dissolution, the company will cease business activities except for winding up affairs and will terminate SEC reporting status.
Voting matters and shareholder proposals
Only one proposal: approval of the Assignment and Dissolution, including authorization for the Board to abandon the process if deemed necessary.
Each Class A share has one vote; each Class B share has twenty votes.
Approval requires a majority in voting power of outstanding common stock.
Board recommends voting "FOR" the proposal.
Board of directors and corporate governance
Board retains discretion to proceed with or abandon the Assignment and Dissolution after stockholder approval.
Board may modify or amend the Plan of Dissolution without further stockholder action.
Certain directors may resign upon appointment of the Assignee.
Latest events from Vicarious Surgical
- Stockholders will vote on dissolving the company, with distributions to them considered unlikely.RBOT
Proxy filing12 Jun 2026 - Net loss narrowed to $7.3M in Q1 2026, but cash only funds operations through Q2 2026.RBOT
Q1 202630 Apr 2026 - Vote on a reverse stock split to support Nasdaq listing and investor access, with Board discretion.RBOT
Proxy filing23 Mar 2026 - Vote sought on a reverse stock split to support Nasdaq listing and broaden investor appeal.RBOT
Proxy Filing13 Mar 2026 - Net loss and expenses declined in 2025, with 2026 cash burn expected to decrease further.RBOT
Q4 20259 Mar 2026 - Robotic system targets untapped surgical markets with advanced intra-abdominal access and dexterity.RBOT
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - All proposals, including director elections and key amendments, were approved without questions.RBOT
AGM 20241 Feb 2026 - Q2 2024 saw improved losses, $73.2M liquidity, and V1.0 system on track for fall integration.RBOT
Q2 20241 Feb 2026 - Operating expenses dropped 17% in Q3 and net loss narrowed as clinical milestones approach.RBOT
Q3 202414 Jan 2026